Valuation of Your Early Drug Candidate
The Art & Science of High M&A Valuation
Getting Ready for a Biopharma Partnering Deal
Must-Know Finance Concepts for Life Sciences Valuations - Part II
This whitepaper discusses which asset valuation methodology is most used by big pharma to evaluate possible partners or acquisitions and an explanation of three fundamental concepts in valuation: risk-adjusted value, cost of capital, and present value.
Demystifying Tech M&A Valuation
Must-Know Finance Concepts for Life Sciences Valuations
The Nuts & Bolts of Due Diligence in Biopharma Partnering
What's Hot and What's Not in Oncology Licensing in 2020?
How to Win at the Partnering Game
In this white paper, Linda Pullan provides a review of the rules of the partnering game – whether it’s partnering from preclinical to late clinical development – to provide an understanding of what to expect in moving from introductions to negotiations of a license or acquisition and how to win with a clear strategy.
What’s Hot & What’s Not in Immuno-Oncology Licensing
Maximizing M&A Value, Minimizing Surprises
Non-Immuno-Oncology and Immuno-Oncology Partnering and Development: What’s the Role of Non-IO in an IO World?